Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib

• DOI: 10.1371/journal.pone.0217340
• Publication Date: 2019-06-20T17:33:45Z
• Authors: Andrés F. Cardona; Alejandro Ruiz-Pa...; Zyanya Lucia Zata...; Fernando Hakim; Enrique Jiménez; Juan Armando Mejía; Juan Fernando Ramón; Nicolás Useche; Sonia Bermúdez; Diego Pineda; Hernando Cifuentes; Leonardo Rojas; Luisa Ricaurte; Luis Eduardo Pino; Carmen Balaña; Oscar Arrieta
• Keywords: Everolimus; Progression-free survival

Purpose To compare the effectiveness of octreotide/everolimus vs. sunitinib for systemic treatment recurrent aggressive meningiomas. Methods 31 patients with or refractory WHO II III meningiomas were examined in two reference centers Colombia. Patients who had (sunitinib, everolimus/octreotide) and a complete follow-up included. Overall survival (OS), progression-free (PFS) toxicities evaluated. Additionally, tissue samples PDGFRβ VEGFR2, their expression was correlated outcomes. Results Twenty-two (72%) female median age 55 years (SD±15.3). The most prevalent histology anaplastic meningioma 20 (65%) 48% suffering from three previous relapses before start treatment. A total 14 received combination therapy octreotide/everolimus, 11 remaining 6 other second-line agents. Median OS 37.3 months (95%CI 28.5–42.1) PFS during everolimus/octreotide (EO) (Su) 12.1 9.2–21.1) 9.1 6.8–16.8); p = 0.43), respectively. group treated EO→Su→Bev sequence (1st/2nd/3rd line) 6.5 longer than Su→EO→Bev (36.0 29.5 months) (p 0.0001). When analyzing molecular markers, positive negative VEGFR2 associated both PFS. Conclusion Sunitinib have similar efficacy safety management meningioma. are better